Hudson Value Partners’s ARK Genomic Revolution ETF ARKG Stock Holding History
Bought
Maintained
Sold
Other funds holding ARKG
MCMC
Hudson Value Partners's ARKG Position: Q1 2022 in Review
Hudson Value Partners sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2022, closing a stake of 14,605 shares — an estimated $894K sold.
Hudson Value Partners first reported a position in ARKG in Q2 2021 and held it in 3 quarters. The position peaked at $1.15M in Q2 2021. 388 funds tracked by Wall St. Rank hold ARKG as of Q1 2022.
- Hudson Value Partners reported no remaining ARK Genomic Revolution ETF position as of Q1 2022 after selling out during the quarter.
- Hudson Value Partners sold 14,605 ARK Genomic Revolution ETF shares in Q1 2022, an estimated $894K.
- Hudson Value Partners first reported a position in ARK Genomic Revolution ETF in Q2 2021 and held it in 3 quarters.
- Hudson Value Partners's ARK Genomic Revolution ETF position peaked at $1.15M in Q2 2021.
- 388 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2022.
Based on Hudson Value Partners's 13F filing for Q1 2022, filed 14 Apr 2022.